What Integra Treats: Main Uses and Benefits

Integra Dermal Regeneration Template is a specialized, two-layer tool commonly used in reconstructive surgery and the management of complex wounds. Its core purpose is to support the management of complex skin defects, which may assist with maintaining functional stability.

The Dermal Regeneration Template is indicated for the post-excisional treatment of specific thermal injuries (burns) and is relevant for easing the symptomatic burden associated with conditions like scar contractures. Its use is commonly applied across conditions presenting with acute episodes of tissue loss and is relevant when supportive symptom management is appropriate for complex tissue defects. The device is considered relevant in contexts involving heightened systemic burden.

This therapeutic approach addresses symptoms that create noticeable physiological strain and helps patients cope more steadily with their symptomatic burden. The device provides supportive relief when symptoms interfere with routine activities, contributing to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Symptoms related to physical discomfort

The use of Integra assists with maintaining functional stability in clinical settings that involve acute or unstable symptom patterns. It is commonly used to help with symptoms related to inflammatory or irritative states and may assist with managing symptoms that become more disruptive during flare-ups of chronic wounds.

Regulatory References

1. FDA Summary of Safety and Effectiveness Data

The eligibility for using Integra Dermal Regeneration Template (IDRT) is determined by absolute contraindications related to its bovine collagen and chondroitin components, as well as the condition of the wound site.

Populations and Conditions Contraindicated for Use

Use of IDRT is contraindicated in two main populations, as defined by the official regulatory label:

• Patients with a known hypersensitivity (allergy) to bovine collagen or chondroitin materials.
• Patients with clinically diagnosed infected wounds.

Restricted and Conditional Use

Certain populations and wound conditions require caution or are restricted:

• Pregnancy: There are no clinical studies evaluating IDRT in pregnant women. Use is restricted to cases where the anticipated benefit clearly outweighs the risk.
• Wound Site Condition: The device must not be applied to a wound bed with nonviable tissue or inadequate hemostasis (uncontrolled bleeding), as the material will not incorporate successfully.
• Age Groups: The official regulatory label does not impose specific restrictions for pediatric or geriatric use for the primary indications (severe burns and scar contractures).

Interactions with other medicines and products

The Integra Dermal Regeneration Template is classified as a non-pharmacological, bi-layer medical device intended for local application during surgical procedures, not a systemically absorbed drug. Its components, including bovine collagen, glycosaminoglycan, and polysiloxane (silicone), are designed for local tissue integration or provide a temporary physical barrier, and do not enter the bloodstream in a manner that influences systemic drug processes.

---

Official Regulatory Status of Systemic Interactions

Interaction Type	Status in Regulatory Labeling
Drug–Drug Interactions	None documented.
Metabolic (CYP) Interactions	None documented.
Food, Alcohol, or Herbal Products	None documented.
Timing / Separation Rules	None required.

---

Official regulatory documentation, such as the FDA Summary of Safety and Effectiveness Data, confirms that the device does not have a conventional pharmacological interaction profile. The device's components do not induce or inhibit drug-metabolizing enzymes (like CYP450) or interfere with drug transporters. Consequently, the labeling does not list any formal contraindications, restrictions, or required timing separation windows for co-administered systemic medications. The use of Integra does not require dosage adjustments or precautions for other drugs based on an interaction risk.

Guided Cellular Regeneration and Scaffolding

This mechanism engages the porous inner layer, a matrix of collagen and glycosaminoglycan, which serves as an acellular scaffold. This physical structure provides the precise three-dimensional template and cues that facilitate the infiltration of the host's own fibroblasts and endothelial cells into the wound bed. This controlled infiltration initiates a cascade of Extracellular Matrix (ECM) deposition and angiogenesis, resulting in the formation of vascularized neodermis.

Physiological Barrier and Local Homeostasis

This domain involves the outer polysiloxane (silicone) layer, which provides an immediate, non-porous seal. This mechanism primarily modulates the local physiological environment by creating a physical barrier that restricts material exchange with the external environment. Crucially, it limits excessive transepidermal water and protein loss, thereby regulating systemic fluid and electrolyte loss—a local environment condition that enables the underlying cellular regeneration pathway.

How Integra Dermal Regeneration Template Is Used

Integra Dermal Regeneration Template is a sterile, bi-layer surgical device used exclusively in a two-stage surgical procedure. The device is applied only in a sterile operating room environment to wounds that have undergone meticulous debridement to ensure a viable tissue bed where hemostasis has been achieved.

Prior to placement, the collagen-based dermal matrix must be prepared by rinsing or soaking in approximately 1 L of sterile saline for a period of about two minutes. The sheet is then cut and shaped to the exact size of the defect, and secured to the wound margins using sutures or staples. The smooth, thin silicone layer is positioned to face outward, functioning as a temporary epidermal covering.

---

Procedural Timing and Administration Conditions

Usage follows a defined schedule to facilitate tissue regeneration. The initial application (Stage 1) requires the device to remain undisturbed for an interval typically ranging from 14 to 28 days. This time frame allows for the formation of a vascularized neodermis.

During this period, a compression dressing or bolster, such as Negative Pressure Wound Therapy (NPWT), must be used to ensure intimate contact between the template and the wound bed. The device must not be used in conjunction with enzymatic debridement agents, Dakin's solution, or petroleum-based products.

Once neodermis formation is complete, the outer silicone layer is surgically removed, and a thin epidermal autograft is placed during the second surgical stage. The application over anatomical areas like joints requires the limb to be positioned in an un-flexed posture during the procedure.

Research Evidence / Overview of Studies for Integra Dermal Regeneration Template

---

Evidence for Use in Severe Thermal Injuries (Severe Burns)

The core research for Integra Dermal Regeneration Template (IDRT) involved prospective clinical trials and post-marketing observational studies that monitored outcomes in patients with severe, full-thickness, or deep partial-thickness burns. These studies contributed to the initial evidence base considered during regulatory review. The populations studied primarily included patients with extensive burns who had limited available skin for immediate standard autografting.

Researchers studied whether the device was successfully incorporated into the wound bed, a measurement often called the device take rate. They also measured the ability of the tissue to accept a subsequent, very thin layer of the patient's own skin (a split-thickness skin graft, or STSG) after the initial matrix had integrated. Studies monitored outcomes related to patient survival and functional outcomes over time, such as the mobility of the affected area.

---

Research on Use in Scar Contracture Repair

Research has explored the use of Integra in reconstructive surgery for conditions characterized by severe scar contractures, often following prior burn injuries. The evidence base here consists of prospective clinical trials and multicenter retrospective surveys that monitored outcomes in adult and pediatric patients across various body sites. The studies monitored outcomes related to functional measures, such as measurable changes in the range of motion at a joint following contracture release, and utilized standardized scales to assess the aesthetic appearance and pliability (softness) of the reconstructed tissue.

---

Areas of Uncertainty and Research Gaps

Despite the foundational research, several areas of uncertainty and evidence gaps remain. The initial regulatory evaluations relied on non-randomized trials or comparisons, meaning the evidence quality varies across studies when compared to large-scale, randomized controlled trials. Comparative evidence is lacking for many potential scenarios, making it difficult to fully contextualize the observed patterns against all other available dermal substitutes and surgical techniques. Furthermore, while long-term follow-up exists, consistent, standardized data on the long-term durability of the reconstructed tissue beyond the five-year mark are still being collected and analyzed.

Common questions about Integra (FAQ)

Q: How long does it typically take to start noticing any change after beginning Integra?

The purpose of the template is to guide the formation of new dermal tissue, known as neodermis. Official product information indicates that this regeneration and vascularization process typically takes between 14 to 21 days following the initial surgical application. This process culminates in the formation of new tissue, leading to the second surgical stage where the outer silicone layer is removed.

Q: Are the side effects of Integra temporary or do they last for the entire treatment period?

Official safety information indicates that complications, such as infection and graft failure, are most associated with the initial dermal regeneration period (14 to 28 days). Regulatory labeling indicates that the device must be removed if certain conditions, such as infection or allergic reaction, occur. The duration of other common localized events depends on the clinical management of the surgical site.

Q: What are the official statements regarding Integra use during pregnancy or breastfeeding?

Regarding pregnancy, regulatory documents state there are no clinical studies available on the device’s use in pregnant women. Caution is advised, and use should only occur if the potential benefit is judged to clearly outweigh the risks. The device's official regulatory documentation currently does not address its use or any precautions related to breastfeeding.

Q: Is Integra considered a high-risk medication by regulatory bodies?

Integra is classified by the FDA as a Class III medical device, which is the category requiring the highest level of regulatory scrutiny, known as Premarket Approval (PMA). This designation confirms the device is restricted to use by prescription from qualified clinicians.

Q: Does Integra affect sleep patterns?

Regulatory safety reporting does not list effects on sleep patterns, such as insomnia or somnolence. This is consistent with the device’s mechanism, as it is a surgically applied, locally acting template and is not systemically absorbed into the bloodstream.

Q: Where can I find the official patient information leaflet (PIL) for Integra?

Official regulatory information, including the Summary of Safety and Effectiveness Data, is publicly available through the FDA’s Premarket Approval (PMA) records for the device. This information is associated with the specific FDA Premarket Approval (PMA) file number P900033.

The Integra Dermal Regeneration Template must be stored and handled according to specific conditions to maintain its sterility and integrity as a medical device.

Storage & Disposal Scope

Requirement	Regulatory Statement
Labeled storage temperature requirements	Store flat at 2 C to 30 C (36 F to 86 F).
Light/moisture protection requirements	The product is provided sterile in a sealed inner foil pouch and an outer pouch.
Stability after opening/reconstitution	Must be applied on the day of excision/debridement after a rinse in sterile saline solution.
Handling requirements	Single-use only; must be handled using sterile technique and must not be re-sterilized.
Packaging-related storage rules	Use only if the packaging is unopened and undamaged to ensure sterility.
Disposal instructions	Discard all opened and unused portions of the product.
Environmental or controlled-waste disposal requirements	Dispose of according to institutional procedures for medical waste.
Child-protection storage requirements	No specific instruction provided due to clinical-setting use.

Storage/Disposal Classifications (High-Level)

Classification	Definition based on Official Documents
Storage condition type	Temperature Controlled and Protected from Freezing.
In-use stability classification	Must be used immediately following preparation.

Connection to the overall storage/disposal profile: Official labeling mandates controlled storage temperatures and strictly prohibits freezing to preserve the material's structure. Handling constraints specify the device is single-use and non-re-sterilizable, requiring sterile technique. Disposal must adhere to institutional protocols for medical waste, with opened, unused product discarded immediately.